← All Compounds
Mechanism Gastric pentadecapeptide. Promotes angiogenesis, tendon/ligament healing, and nitric oxide signaling. Modulates growth factor expression. Half-Life Estimated 15-30 minutes (rapid clearance per He 2022 PK data) Route subcutaneous Frequency 1-2x daily
FDA Category Research peptide (FDA Category 2) Reclassification pending Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
BPC-157
Cat 2 → Pending Cat 1Growth & Recovery · Research peptide (multiple suppliers)
Gastric pentadecapeptide researched for tissue repair, angiogenesis, and anti-inflammatory effects. Not FDA-approved for any indication.
About
Clinical Dosing
200-800 mcg1-2x daily
Not FDA-approved for any indication. Currently FDA Category 2 (restricted). Pending return to Category 1 availability.
Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Dosing Protocol
Source: Sikiric et al., Current Pharmaceutical Design, 2018
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 250 mcg | Maintenance | 0.10 mL (10 units) | Typical research dose, no titration |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial
Citations
- [1]Stable Gastric Pentadecapeptide BPC 157: Novel Therapy. Current Pharmaceutical Design, 24(18), 2012-2032. Link(Reviewed: 2026-02-27)